Volunteer Clinical Associate Professor, Department of Medicine, University of Oklahoma, Oklahoma, OK, USA,Research and Business Development, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, USAInterests: immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signalingSpecial Issues and Topics in IMR Press journalsSpecial Issue in FAK signaling
Dear Colleagues,
I hereby invite you to submit manuscripts on CAR-T cell therapy.
CAR (chimeric antigen receptor) T cell therapy is a novel type of cellular therapy that has shown highly promising results for the treatment of hematological cancers and of other cancer types. The chimeric antigen receptor construct involves signaling peptide, single chain variable fragment (scFv) of antibody that binds to tumor antigen, hinge, different co-stimulatory domains and activation CD3 domains. Once CAR-T cells bind to tumor antigen, the T cell becomes activated leading to killing of tumor cell due to the activation of intracellular signaling and the secretion of cytokines. However, there are still many challenges for this novel therapy, such as its efficacy in solid cancers, overcoming the repressive tumor microenvironment, checkpoint pathways and on-target-off-tumor activity. This issue will focus on CAR design, CAR intracellular signaling, and various ways to improve this therapy such as combination with other immune and anti-cancer cell therapies. It will also highlight novel approaches for CAR-T cell therapy, focus on CAR-T cell therapy against different types of cancer, discuss challenges and present new clinical advances and perspectives in this field.
Dr. Vita Golubovskaya
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.